摘要
Objective: To assess the efficacy of 5%imiquimod cream on undifferentiated vulvar intraepithelial neoplasia (VIN), a disease caused by high-risk human papillomavirus. Design: Prospective, uncontrolled study. Setting: University hospital vulvar clinic. Patients: Twelve consecutive patients treated with 5%imiquimod cream for undifferentiated VIN between March 1, 1999, and May 31, 2001. Intervention: Self-application of 5%imiquimod cream, initially 3 times a week, then adjusted according to tolerance, for up to 7 months according to clinical response. Main Outcome Measures: Therapeutic response, clinically assessed by successive photographs and histologically confirmed for complete responders, was scored as complete, partial (≥50%decrease in lesion size), or failure. Tolerance was evaluated at each visit. Results: A total of 3, 4, and 5 patients achieved complete response, partial response (≥75%reduction in lesion size for all such cases), and failure, respectively. Mean duration of treatment was 3.6 months (37.3 applications), 5.0 months (50.7 applications), and 3.4 months (25.2 applications) for complete responders, partial responders, and failures, respectively. Follow-up after treatment was 5 to 18, 14 to 32, and 2 to 28 months, respectively, with 1 partial responder lost to long-term follow-up. No patient developed invasive carcinoma. All but 2 patients experienced vulvar discomfort, resulting in treatment withdrawal for 3. Two patients had flulike symptoms. Conclusions: Imiquimod cream could be a therapeutic option for undifferentiated VIN. Although poorly tolerated, this self-applied treatment could spare patients, either totally or partially, the classic painful and sometimesmutilating treatments of VIN. Controlled, randomized studies are needed to evaluate its efficacy and tolerance.
Objective: To assess the efficacy of 5%imiquimod cream on undifferentiated vulvar intraepithelial neoplasia (VIN), a disease caused by high-risk human papillomavirus. Design: Prospective, uncontrolled study. Setting: University hospital vulvar clinic. Patients: Twelve consecutive patients treated with 5%imiquimod cream for undifferentiated VIN between March 1, 1999, and May 31, 2001. Intervention: Self-application of 5%imiquimod cream, initially 3 times a week, then adjusted according to tolerance, for up to 7 months according to clinical response. Main Outcome Measures: Therapeutic response, clinically assessed by successive photographs and histologically confirmed for complete responders, was scored as complete, partial (≥50%decrease in lesion size), or failure. Tolerance was evaluated at each visit. Results: A total of 3, 4, and 5 patients achieved complete response, partial response (≥75%reduction in lesion size for all such cases), and failure, respectively. Mean duration of treatment was 3.6 months (37.3 applications), 5.0 months (50.7 applications), and 3.4 months (25.2 applications) for complete responders, partial responders, and failures, respectively. Follow-up after treatment was 5 to 18, 14 to 32, and 2 to 28 months, respectively, with 1 partial responder lost to long-term follow-up. No patient developed invasive carcinoma. All but 2 patients experienced vulvar discomfort, resulting in treatment withdrawal for 3. Two patients had flulike symptoms. Conclusions: Imiquimod cream could be a therapeutic option for undifferentiated VIN. Although poorly tolerated, this self-applied treatment could spare patients, either totally or partially, the classic painful and sometimesmutilating treatments of VIN. Controlled, randomized studies are needed to evaluate its efficacy and tolerance.
